the United Kingdom. That series, though small (141 cases), is of considerable importance in any attempt to obtain quantitative data on the risks consequent upon the use of this radioisotope. It is the only series able to report the outcome for all cases (131) resident in the United Kingdom. This was done by Boyd et al. in 1968 . Significant deposition of thorium in the neck occurred in 8 patients (7% of 109 patients who survived at least one year following injection). In 2 patients the deposition was bilateral and in 5 it had produced symptomsrecurrent laryngeal nerve palsy in four. An earlier survey by soft-tissue X-rays of the neck had shown some thorium in the soft tissues of the neck in 30% of 60 cases examined.
A similar picture to that seen in the neck was progressive fibrosis following the injection of Thorotrast into the cerebrospinal pathways with the development of a progressive cauda equina lesion in 7 out of 10 patients at a mean interval of 12 years. The leisurely 10-month interval between the presentation of the papers and their publication, complete with almost as many typing errors as now regularly appear in The Times, illustrates the failure of the symposium organizers, editors, contributors and publishers to appreciate just how critical some of the new information was to the rest of the human race who were not privileged to attend the conference. The editors enthusiastically echoed the ivory tower attitude of most scientists studying the disease: 'The AIDS epidemic has provided unique opportunities for investigation of interrelationships among viral agents, the immune system, and neoplasia in man', as if it was of no more public health importance than Di George syndrome or rabies.
In my opinion the evidence contained in the first 100 pages of the book, combined with the evidence which had already been published before the symposium, had already verified beyond all reasonable doubt the hypothesis that all cases of AIDS are simply caused by infection with a nononcogenic, cytopathic, lymphotropic retrovirus (called HTLV-111 or LAV or ARV) new to man, which produces a persistent cell-free viraemia, is transmitted like hepatitis B virus (HBV) and has an incubation period from infection to serious illness and death of several years. However, none of the contributors at the symposium put forward this unifying hypothesis; few of them would have agreed with its validity even if it had been; and even fewer would have comprehended the practical implications.
It is the simple fact that HTLV-l1I1 is a retrovirus which is not oncogenic, but is cytopathic and highly replicative in vivo, which makes the future of all human societies on earth beyond the next few years so precarious. Life-long persistence of a retrovirus in its host (which is the way of life of all retroviruses) which is also highly replicative in vivo (which is very unusual for any retrovirus) is characterized by frequent changes in the envelope glycoprotein of infectious virions via mutation, genetic recombination or, rarely, phenotypic mixing. Not only do these envelope changes enable replicative retroviruses to escape the immune mechanisms by antigenic drift within each individual host, it makes the production of an effective vaccine theoretically impossible. Furthermore, a major change in envelope glycoprotein (antigenic shift) can have drastic effects on a retrovirus's biological functions, enabling it to use different host cell receptors, replicate in different cells, or even infect new host species.
During the 10 months which elapsed between the presentation of the papers at the symposium in Utah and their publication, restriction enzyme mapping of the nucleotide sequences of HTLV-111 carried out in several laboratories and recently published have, not surprisingly, confirmed that there are huge differences between the molecular structure of one virus and another. The tiny number of different isolates of HTLV-I 11 which have so far been characterized already comprise a spectrum ranging from closely to distantly related viruses.
At present HTLV-l 11 is transmitted much like HBV and consequently it will spread inexorably through the population of the Third World even without homosexual anal intercourse, intravenous drug abuse, clotting factor or blood transfusions speeding it on its way. In the crowded squalor in which the majority of mankind lives, 'intimate contact' -as contributing scientists in this book coyly call sexual intercourseis entirely superfluous to the slow but steady spread of any persistent cell-free viraemic disease.
Many scientists have asserted that HTLV-l11, unlike HBV, is also transmitted to women by infected men merely by heterosexual vaginal intercourse, but the evidence supporting this hypothesis is tenuous. Nevertheless HTLV-l1I1 has already been isolated from mononuclear cells in semen and saliva of asymptomatic carriers. The antigenic drift and shift which has already produced innumerable antigenic strains of HTLV-1 11 may at any time allow the development of strains which can use the receptors of cervical, urethral, buccal or respiratory mucosal cells for attachment and replication within them, thereby enabling transmission to occur not only like HBV but also by the respiratory and oral routes. With such a prolonged asymptomatic incubation period, several years will elapse before strains using new transmission routes will surface as patients with AIDS.
The retrovirus which causes maedi-visna in sheep, is one of the very few non-oncogenic retroviruses known to cause disease in any animal. it is a member of the subfamily Lentivirinae and causes a classic slow virus disease. It has evolved to be transmitted either by respiratory aerosols, saliva, mother's milk or faeces. Infection produces a 100% mortality after an asymptomatic incubation period of 2 to 8 years without the virus even being cytopathic to the peripheral blood leukocytes which it persistently infects, and in which it replicates quite slowly compared with The editors, in the one-page preface which is all that ties together the 30 diverse papers delivered at the symposium, used two and a half precious lines to inform the world that 'The cost of travel and subsistence for invited speakers and discussants was borne by Schering, as was the cost of refreshments during nightly mixers held to promote discussion'.
Nero fiddled while Rome burned, but at least he knew it was burning. Did not even one of the molecular biologists, imbibing ideas along with their free 'refreshments', realize that the subject matter of their symposium was the molecular biological equivalent of nuclear war against man; and that the tiny finger of HTLV-l1, not that of the resident incumbent in the White House or Kremlin, had already pressed the molecular button? A number of books have been published recently on the subject of prescribing in pregnancy; this book is unique in concentrating on pharmacokinetics. The study of pharmacokinetics in pregnancy is a major challenge, not only because of the alterations in maternal physiology induced by pregnancy, but also because pregnancy adds several compartments to the pharmacokinetic model, i.e. the fetus, placenta and amniotic fluid, which are important in their own right. The pregnant woman and her fetus therefore present unique problems for pharmacokinetic analysis. The authors of this book are very well qualified to meet such a challenge: Beatrice Krauer is a paediatrician and clinical pharmacologist; Felix
